Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements
MWN-AI** Summary
Movano Health, a leader in health technology, has achieved significant milestones with its proprietary cuffless blood pressure device, demonstrating accuracy aligned with FDA standards during a recent clinical study involving 81 participants. The device, leveraging an advanced System-on-a-Chip (SoC), reported an overall mean absolute difference (MAD) of 4.9 mmHg, surpassing the 7 mmHg threshold established for wearable, cuffless blood pressure monitors. This advancement is timely, as nearly half of Americans aged 20 and older are affected by hypertension, underscoring the critical need for effective blood pressure monitoring solutions.
The clinical trials utilized the latest version of Movano’s wrist-worn prototype, enhanced with an additional 12 mmWave antennas and a custom integrated circuit, resulting in improved data collection and comfort. Moreover, the device offers the capability to monitor various vital signs, including pulse rate, blood oxygen saturation, respiration rate, and ECG waveforms. The study indicated a notable increase in signal reliability and accuracy compared to prior iterations.
Movano Health’s CEO, John Mastrototaro, expressed optimism about the performance of their SoC and its potential to lead to FDA clearance, marking a crucial step in the commercialization of this innovative wearable technology. Looking ahead, the company is planning a pivotal trial aimed at meeting FDA clinical requirements, further advancing its goal to deliver a comprehensive and user-friendly blood pressure monitoring solution. As Movano Health continues to refine its technologies, it aims to transform how individuals and clinicians manage high blood pressure, leveraging wearable technology to provide actionable health insights.
MWN-AI** Analysis
Movano Health (Nasdaq: MOVE) has made significant strides with its proprietary cuffless blood pressure device, recently demonstrating accuracy within FDA standards. With an impressive mean absolute difference of 4.9 mmHg—well below the 7 mmHg threshold—Movano’s device stands ready to tap into a growing market driven by the increasing prevalence of hypertension in the U.S. As over 122 million Americans suffer from high blood pressure, Movano’s innovations present a timely opportunity for investment consideration.
The company’s reliance on advanced radio frequency (RF) technology and a System-on-a-Chip (SoC) has enhanced both accuracy and user comfort. The clinical results, based on a robust study involving 81 participants, suggest a promising path to commercialization, especially given Movano’s upcoming pivotal trial aimed at FDA clearance.
**Market Position and Competition**: As wearable technology continues to gain traction, Movano's unique offering could help it carve out a significant niche in the health tech market. Competitors are also innovating in this space; however, Movano’s successful prototype and focus on affordability and ease of use may give it an edge. The integration of measuring additional vital signs solidifies the device as a comprehensive health monitor, further broadening its appeal.
**Investment Strategy**: Given the successful clinical study outcomes and the impending FDA trial, Movano appears positioned for growth. However, potential investors should closely monitor the progress of regulatory approvals and the efficacy of further studies. Price volatility is likely as the market reacts to news updates.
In summary, Movano Health presents a compelling investment opportunity for those seeking exposure to the health technology sector but proceed with caution, remaining aware of the inherent risks associated with FDA processes and market competition.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device
PLEASANTON, Calif. , April 22, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wearable, cuffless blood pressure measuring devices (IEEE1708a-2019).
Hypertension has reached epidemic proportions in the United States and is often labeled the silent killer as many don't know they are affected. According to the American Heart Association, high blood pressure affects half of Americans ages 20 years and older – or more than 122 million people – and 59 million Americans have prehypertension, making longitudinal blood pressure monitoring arguably the next frontier in continuous monitoring and the single most important clinical metric. Movano Health's cutting-edge RF technology has the potential to empower individuals and their clinicians to better monitor and manage high blood pressure on a daily basis.
This most recent study incorporated the latest version of the Company's wrist-worn wearable prototype, featuring an additional 12 mmWave antennas. When combined together with the Company's custom IC, the wearable delivers enhanced data collection with less impact of placement while also featuring a slimmer design, making it easier and more comfortable to wear. In addition, the new wearable can monitor a host of other vital signs including pulse rate, blood oxygen saturation (SpO 2 ), respiration rate and ECG waveforms. The increased number of RF antennas, as well as the addition of new signals for enhanced sensor fusion, has facilitated a marked increase in sensitivity and signal reliability from the Company's previous design, resulting in an even higher level of accuracy than the prior study, and represents a significant leap forward in cuffless blood pressure monitoring. With a more consumer-oriented device just a few months away, Movano Health is currently in the planning stage of a pivotal trial to satisfy FDA clinical requirements.
The IRB-approved study was conducted at the Movano Health Clinical Lab and assessed the accuracy of the Company's wrist-worn prototype compared to a hospital-grade FDA-cleared blood pressure monitor. The study measured the blood pressure of each participant multiple times, including while under stress.
"After multiple iterations of optimizing our IC, antennas, and AI algorithms, our SoC produced much cleaner signals with significantly less noise in this study than our multiple chip solution did previously," said Michael Leabman , CTO and founder of Movano Health. "Most importantly, we learned that our machine learning models hold across a broader range of blood pressure values than in prior studies, which is crucial for our pursuit of commercializing an FDA cleared cuffless blood pressure wearable."
"Our goal is to deliver a more accurate, flexible and cost-effective wearable blood pressure solution, and this study reveals the initial payoff of our investment in proprietary mmWave sensor technology. We are extremely encouraged with the performance of our SoC and look forward to the next step of confirming the platform in pivotal studies, which would open a pathway to regulatory filings," said John Mastrototaro , CEO of Movano Health.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.
Movano Health's proprietary technologies and wearable medical device solutions enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/ .
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to the commercial launches of the Evie Ring and EvieMED; our expectations regarding potential commercial opportunities and addressable markets; planned cost-cutting initiatives; anticipated FDA clearance decisions with respect to our products; expected future operating results; product development efforts and product releases; clinical trial and regulatory initiatives; commercial partner activities; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
SOURCE Movano
FAQ**
How does Movano Inc. MOVE's proprietary System-on-a-Chip technology enhance the accuracy of its cuffless blood pressure device compared to traditional methods?
What steps is Movano Inc. MOVE taking to prepare for the pivotal trial required for FDA clearance of its cuffless blood pressure wearable?
In light of the recent clinical study, how does Movano Inc. MOVE plan to differentiate its wearable device in a crowded health tech market?
Can Movano Inc. MOVE's advanced RF-enabled technology expand to include additional health monitoring features, and what implications does this have for long-term health management?
**MWN-AI FAQ is based on asking OpenAI questions about Movano Inc. (NASDAQ: MOVE).
NASDAQ: MOVE
MOVE Trading
0.69% G/L:
$13.3529 Last:
11,405 Volume:
$13.3979 Open:
